26782 Federal Register / Vol. 74, No. 106 / Thursday, June 4, 2009 / Rules and Regulations 

[FR Doc. E9–12991 Filed 6–3–09; 8:45 am] 

BILLING CODE 4910–13–P 

SECURITIES AND EXCHANGE 

COMMISSION 

17 CFR Parts 239 and 274 

[Release Nos. 33–8998A; IC–28584A; File 

No. S7–28–07] 

RIN 3235–AJ44 

Enhanced Disclosure and New 

Prospectus Delivery Option for 

Registered Open-End Management 

Investment Companies 

AGENCY: Securities and Exchange 

Commission. 

ACTION: Final rule; correction. 

SUMMARY: In connection with rules 

adopted in Release No. 33–8998 

(January 13, 2009), which appeared in 

the Federal Register on January 26, 

2009 (74 FR 4546), the Securities and 

Exchange Commission is making 

technical corrections to Form N–1A and 

Form N–4. Specifically, the Commission 

is correcting certain cross-references 

appearing in each Form and correcting 

a citation appearing in Form N–1A. The 

citation being corrected was originally 

adopted in its incorrect form in Release 

No. IC–23064 (Mar. 13, 1998), which 

appeared in the Federal Register on 

March 23, 1998 (63 FR 13916). 

DATES: Effective Date: June 4, 2009. 

FOR FURTHER INFORMATION CONTACT: 

Kieran G. Brown, Senior Counsel, Office 

of Disclosure Regulation, at (202) 551– 

6784, Division of Investment 

Management, Securities and Exchange 

Commission, 100 F Street, NE., 

Washington, DC 20549–5720. 

SUPPLEMENTARY INFORMATION: The 

Commission is making the following 

corrections to Release No. 33–8998 

(January 13, 2009), which was 

published in FR Doc E9–1035 appearing 

on page 4546 in the Federal Register on 

January 26, 2009: 

Note: The text of the form does not, and 

these amendments will not, appear in the 

Code of Federal Regulations. 

1. On page 4588, second column, 

amendment 13, paragraph m.ii., 

beginning on line four, revise the 

reference ‘‘Items 17(d) and 22(b)’’ to 

read ‘‘Items 17(d) and 23(b)’’. 

2. On page 4588, second column, 

amendment 13, paragraph m.iii., on the 

second line, revise ‘‘reference’’ to read 

‘‘references’’, and on the third line, 

revise the reference ‘‘Item 22(a)’’ to read 

‘‘Item 23(a)’’. 

3. On page 4593, second column, add 

amendment 13(a) to read as follows: 

13(a). Form N–1A (referenced in 

§§ 239.15A and 274.11A) is amended 

by: 

a. In the General Instructions, revising 

the citation ‘‘[15 U.S.C. 80a–24f–2]’’ in 

paragraph B.3. to read ‘‘[15 U.S.C. 80a– 

24(f)]’’; and 

b. In newly redesignated Item 17(c)(2), 

revising the reference ‘‘paragraph (d)(1)’’ 

to read ‘‘paragraph (c)(1)’’. 

4. On page 4593, second column, 

amendment 14, beginning on the fourth 

line and continuing on to the third 

column, revise the reference ‘‘Item 

27(b)(ii) of Form N–1A’’ to read ‘‘Item 

26(b)(4) of Form N–1A’’; in the third 

column on the third line, revise the 

reference ‘‘Item 27(b)(ii) equation’’ to 

read ‘‘Item 26(b)(4) equation’’; and in 

the third column on the fourth line, 

revise the reference ‘‘Item 20(b)(ii)’’ to 

read ‘‘Item 21(b)(ii)’’. 

Dated: May 28, 2009. 

Elizabeth M. Murphy, 

Secretary. 

[FR Doc. E9–12956 Filed 6–3–09; 8:45 am] 

BILLING CODE 8010–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

21 CFR Part 524 

[Docket No. FDA–2009–N–0665] 

Ophthalmic and Topical Dosage Form 

New Animal Drugs; Change of 

Sponsor; Diclofenac; Ivermectin Otic 

Suspension 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Final rule. 

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 

animal drug regulations to reflect a 

change of sponsor for diclofenac sodium 

cream and ivermectin otic suspension 

from IDEXX Pharmaceuticals, Inc., to 

Boehringer Ingelheim Vetmedica, Inc. 

DATES: This rule is effective June 4, 

2009. 

FOR FURTHER INFORMATION CONTACT: 

David R. Newkirk, Center for Veterinary 

Medicine (HFV–100), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 240–276–8307, 

e-mail: david.newkirk@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: IDEXX 

Pharmaceuticals, Inc., 7009 Albert Pick 

Rd., Greensboro, NC 27409, has 

informed FDA that it has transferred 

ownership of, and all rights and interest 

in, NADA 141–186 for SURPASS 

(diclofenac sodium) topical cream and 

NADA 141–174 for ACAREXX 

(ivermectin) otic suspension to 

Boehringer Ingelheim Vetmedica, Inc., 

2621 North Belt Highway, St. Joseph, 

MO 64506–2002. Accordingly, the 

regulations are amended in 21 CFR 

524.590 and 524.1195 to reflect the 

change of sponsorship. 

This rule does not meet the definition 

of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because 

it is a rule of ‘‘particular applicability.’’ 

Therefore, it is not subject to the 

congressional review requirements in 5 

U.S.C. 801–808. 

List of Subjects in 21 CFR Part 524 

Animal drugs. 

■ Therefore, under the Federal Food, 

Drug, and Cosmetic Act and under 

authority delegated to the Commissioner 

of Food and Drugs and redelegated to 

the Center for Veterinary Medicine, 21 

CFR part 524 is amended as follows: 

PART 524—OPHTHALMIC AND 

TOPICAL DOSAGE FORM NEW 

ANIMAL DRUGS 

■ 1. The authority citation for 21 CFR 

part 524 continues to read as follows: 

Authority: 21 U.S.C. 360b. 

§ 524.590 [Amended] 

■ 2. In paragraph (b) of § 524.590, 

remove ‘‘065274’’ and in its place add 

‘‘000010’’. 

§ 524.1195 [Amended] 

■ 3. In paragraph (b) of § 524.1195, 

remove ‘‘065274’’ and in its place add 

‘‘000010’’. 

Dated: May 27, 2009. 

Bernadette Dunham, 

Director, Center for Veterinary Medicine. 

[FR Doc. E9–13015 Filed 6–3–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

33 CFR Part 165 

[Docket No. USCG–2009–0267] 

RIN 1625–AA00 

Safety Zone; Sea World June 

Fireworks; Mission Bay, San Diego, CA 

AGENCY: Coast Guard, DHS. 

ACTION: Temporary final rule. 

SUMMARY: The Coast Guard is 

establishing a safety zone, on the 

navigable waters of Mission Bay in